Company Overview - Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions primarily in North America and Europe [2] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering trusted self-care solutions that do not require a prescription, ensuring accessibility and choice for consumers across various molecules, dosage forms, and value tiers [2] Business Model - Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [3] Upcoming Events - The President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to participate in one-on-one investor meetings at the Barclays Global Consumer Staples Conference on September 3rd, 2025 [1]

Summary of Conference Call Company Overview - The company discussed its ongoing strategy, emphasizing that it is on track with its 3S plan: stabilizing the business, streamlining operations, and strengthening the brand [1][2] - The company operates in a dynamic consumer environment, particularly in the U.S. market [2] Key Industry Insights - The U.S. store brand is gaining market share, with a category-led growth model showing meaningful results [3][4] - Infant formula, which constitutes about 10% of revenue, remains a strategic priority, with investments calibrated to balance resilience and maximize returns [3][7] - The fastest-growing segment of the infant formula market currently lacks a store brand equivalent, presenting a significant opportunity [8] Financial Performance - The company reaffirmed its fiscal year 2025 financial outlook, expecting organic net sales growth towards the lower end of the target range of 1.5% to 4.5% [8] - The Americas business is expected to drive growth, with a projected organic growth of approximately $200 million in the second half compared to the first half [9] - The OTC business is anticipated to contribute 75% of the growth, with net new business wins of $70 to $80 million [10] - The company is on track to deliver an adjusted gross margin target of 40% [11] Strategic Initiatives - Project Energize and supply chain reinvention are yielding tangible benefits, with brand-building investments showing early results [5] - The company is focusing on regaining share among new mothers in the infant formula category, with new SKUs being rolled out [22][24] - The company has seen a strengthening of store brand OTC share, benefiting from consumer trading down to private label products [28] Market Dynamics - The company did not experience significant destocking at retail, and its OTC store brand has grown share [26] - The company is leveraging its extensive portfolio of 100 molecules to drive growth across multiple brands and geographies [35][38] - The UK market has achieved 80% household penetration, indicating strong brand presence [40] Future Outlook - The company expects significant revenue growth from the recovery of the infant formula segment and increasing store brand OTC household penetration [66] - There is a focus on improving operational leverage and expanding into new markets to enhance margins [71] - The company aims to improve free cash flow over net sales and reduce net leverage to attract more investors [76] Additional Considerations - The company anticipates a potential impact of $10 to $20 million on COGS due to tariffs, with plans to offset this through pricing strategies [61][63] - The company is committed to long-term value creation and is focused on executing its strategy with discipline [15][16]

Core Insights - The performance of Perrigo's international operations is critical for understanding its financial strength and growth potential [1][2][3] Group 1: International Revenue Performance - Perrigo's total revenue for the quarter was $1.06 billion, a decrease of 0.9% from the previous year [4] - Revenue from "All other countries" was $23.7 million, accounting for 2.2%, which was a surprise decrease of 14.75% compared to the expected $27.8 million [5] - Europe generated $421.7 million, constituting 39.9% of total revenue, exceeding the projected $398.44 million by 5.84% [6] Group 2: Future Revenue Forecasts - Analysts expect Perrigo to report total revenue of $1.12 billion in the current fiscal quarter, indicating a 3% increase from the prior year [7] - For the full year, total revenue is projected at $4.44 billion, reflecting a 1.6% increase from the previous year [8] Group 3: Market Context and Stock Performance - The company's reliance on international markets presents both opportunities and challenges, necessitating close monitoring of revenue trends [9] - Perrigo's stock has declined by 18.1% over the past month, contrasting with a 2.7% increase in the Zacks S&P 500 composite [13]

Core Viewpoint - Perrigo (PRGO) has experienced a significant downtrend, with a 16.3% decline in stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with a reading below 30 typically indicating this condition [2]. - PRGO's current RSI reading is 21.24, indicating that the heavy selling pressure may be exhausting itself, which could lead to a reversal in the stock's trend [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts regarding an increase in earnings estimates for PRGO, with a 0.3% rise in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [7]. - PRGO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Core Insights - Perrigo (PRGO) reported adjusted earnings of 57 cents per share for Q2 2025, missing the Zacks Consensus Estimate of 59 cents, but showing a year-over-year increase of 7.5% primarily due to lower interest expenses [1][7] - Net sales decreased by 0.9% year-over-year to $1.06 billion, falling short of the Zacks Consensus Estimate of $1.08 billion, attributed to lost sales from exited businesses and product lines, although partially offset by favorable currency movements [1][2] Sales Performance - Sales dropped 2.5% year-over-year due to exited businesses and product lines, but were positively impacted by a 1.7% favorable currency effect; at constant currency, sales fell 2.6% [2] - Organic net sales declined by 0.1%, indicating a slight decrease when excluding acquisitions, divestitures, and currency impacts [2] Segment Analysis - Consumer Self Care Americas (CSCA) reported net sales of $622 million, down 1.9% year-over-year, with growth in Nutrition, Healthy Lifestyle, and Upper Respiratory categories offset by declines in Digestive Health and Oral Care; organic net sales also fell by 1.9% [4] - Consumer Self Care International (CSCI) reported net sales of $434 million, up 0.7% year-over-year, driven by favorable currency translation and organic sales growth, although at constant currency, sales decreased by 3.5%; organic sales increased by 2.7% [5] Financial Guidance - Perrigo lowered its financial guidance for total sales in 2025, now expecting growth towards the lower end of the previously issued range of 0-3%, primarily due to challenges in the infant formula industry and market consumption trends [6][10] - Despite the downward revision in sales, the company maintained its adjusted EPS guidance of $2.90-$3.10, with an adjusted gross margin around 40% and an adjusted operating margin near 15% [10] Market Reaction - Following the guidance revision, Perrigo's stock price declined by 6% during pre-market trading [6]

Financial Data and Key Metrics Changes - Perrigo's organic net sales growth in Q2 was flat compared to the prior year, with OTC brand growth of 3.6% [9] - Year-to-date organic growth was also flat, but up nearly 1% excluding prior year benefits and lost distribution [9] - Gross margin declined due to divested businesses and isolated production variability in infant formula, with organic operating income growth at 28.3% year-to-date [11][30] - EPS in Q2 grew 7.5% or 12.5% organically, and year-to-date EPS increased by over 50% organically [12][35] Business Line Data and Key Metrics Changes - The infant formula business net sales grew 9%, driven by store brand formula, while the Good Start brand experienced a significant decline due to lost distribution [6][16] - Pain and sleep aids grew 8%, contributing to total growth, while upper respiratory products added 0.7 points primarily from new distribution [12][13] - OTC brands delivered organic net sales growth of 3.6% year-over-year, with Jungle Formula growing 14% and Compie achieving record share in several European markets [13][14] Market Data and Key Metrics Changes - Declining total category consumption in the U.S. and decelerating consumption in the EU limited top-line growth, but store brands gained share as consumers sought value [10] - Store brand OTC is gaining share, with Perrigo's allergy product sales up almost 19% at a key retailer despite overall category decline [20][64] - The company is seeing an acceleration in consumers trading down to private label products, with store brand OTC gaining volume and unit share [64] Company Strategy and Development Direction - The company is focused on its 3S plan: stabilize, streamline, and strengthen, with significant steps taken to enhance its self-care organization [5][8] - The sale of the derma cosmetics business for up to EUR 327 million is aimed at sharpening strategic focus on core high-growth brands [6][21] - The company is scaling its category-led market activation growth model to unlock portfolio potential and enhance brand building activities [7][23] Management's Comments on Operating Environment and Future Outlook - Management described the market as fluid and volatile, with heavy promotions from competitors impacting share growth expectations [44] - Despite challenges, the company remains confident in achieving its EPS target, needing only a 3% increase in the second half compared to the previous year [48][49] - The company reaffirmed its full-year EPS outlook, expecting strong double-digit growth despite anticipated lower net sales growth [38][90] Other Important Information - The company is on track to achieve its 2025 operating cash flow conversion target of approximately 100% to adjusted net income [36] - Net leverage to adjusted EBITDA is currently at 3.9x, with a target of approximately 3.5x by year-end [36][37] - The company plans to offset tariff impacts through strategic pricing actions and supply chain adjustments [40][63] Q&A Session Summary Question: Insights on the infant formula market and competitor responses - Management noted that the market is fluid with heavy promotions from brands, and while store brand volume continues to grow, share growth has been dampened by new entrants [44][45] Question: Building blocks for achieving guidance in the second half - Management confirmed that the EPS requirement for the second half aligns with guidance, with significant growth expected from new OTC store brand contracts and improved demand generation activities [51][53] Question: Strategic pricing actions and retailer conversations - Management indicated that discussions with retailers are positive, with expectations to offset tariff impacts through pricing actions across both branded and private label OTC [62][63] Question: Changes in expectations for Opill and marketing plans - Management expressed satisfaction with Opill's performance, noting double consumption and plans to continue targeted marketing to specific consumer cohorts [74][75] Question: Confidence in addressing increased product scrap in infant formula - Management reassured that the increased scrap was an isolated incident caught by quality systems, and confidence is high that it will not continue to impact margins [82][84] Question: Long-term guidance implications from updated expectations on infant formula - Management stated that while the ramp-up has been slower than expected, there is no change to long-term outlook, and efforts to rebuild market share continue [86][87]

Financial Data and Key Metrics Changes - Perrigo's organic net sales growth in Q2 2025 was flat compared to the prior year, with OTC brand growth of 3.6% [8][10] - Gross margin declined by 250 basis points, impacted by divested businesses and isolated production variability in infant formula [11][30] - EPS in the quarter grew by 7.5% or 12.5% organically, with year-to-date EPS growth exceeding 50% organically [12][34] Business Line Data and Key Metrics Changes - The infant formula business net sales grew by 9%, driven by store brand formula, while the Good Start brand experienced a significant decline due to lost distribution [6][16] - Pain and sleep aids grew by 8%, contributing positively to overall growth, while the digestive health category faced challenges due to lower consumption of proton pump inhibitors [12][14] - OTC brands delivered organic net sales growth of 3.6%, with Jungle Formula and Compie achieving significant market share gains [13][14] Market Data and Key Metrics Changes - Store brands are gaining share in volume and unit share as consumers seek value amidst economic uncertainty [10][12] - The U.S. market is experiencing declining total category consumption, while the EU is seeing decelerating consumption trends [10][11] - Perrigo's allergy product sales at a key retailer increased by almost 19% year-to-date, contrasting with a category decline of over 2% [19] Company Strategy and Development Direction - The company is focused on its 3S plan: Stabilize, Streamline, and Strengthen, with significant progress made in stabilizing the infant formula business and streamlining operations [5][26] - An agreement to sell the derma cosmetics business for up to EUR 327 million is expected to sharpen strategic focus on core high-growth brands [6][21] - The company aims to enhance its category-led market activation growth model to unlock portfolio potential and improve execution [22][23] Management's Comments on Operating Environment and Future Outlook - Management described the market as fluid and volatile, with heavy promotional activity from competitors impacting share growth expectations [44][45] - Despite challenges, the company remains confident in achieving its EPS target range of $2.9 to $3.1 per share, equating to strong double-digit growth [38][88] - Management acknowledged the slower-than-expected recovery in the infant formula business but emphasized ongoing demand generation efforts [46][84] Other Important Information - Year-to-date organic gross profit increased by 3.8%, primarily due to recovery in the infant formula business [31] - The company is on track to deliver a full-year gross margin of approximately 40% [30] - Operating cash flow for the year to date was $11 million, with cash on the balance sheet at $454 million [35][36] Q&A Session Summary Question: Insights on the infant formula market and competitor responses - Management noted that the market is fluid, with brands heavily promoting to gain share, and acknowledged that their shelf placement is not optimal at certain retailers [44][45] Question: Building blocks for achieving guidance in the second half - Management confirmed that the EPS requirement for the second half aligns with guidance, emphasizing confidence in OTC store brand growth and infant formula recovery [49][52] Question: Strategic pricing actions and retailer conversations - Management indicated that discussions with retailers regarding pricing are positive, with expectations to offset tariff impacts through pricing actions and supply chain adjustments [61][62] Question: Changes in expectations for Opill and marketing plans - Management expressed satisfaction with Opill's performance, noting double consumption growth and plans to continue investing in brand awareness [72][74] Question: Increased product scrap in infant formula and future confidence - Management clarified that the increased product scrap was an isolated issue caught by quality systems, and they are confident it will not continue to impact margins [80][82]

Core Viewpoint - Perrigo reported quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.59 per share, but showing an increase from $0.53 per share a year ago, indicating a -3.39% earnings surprise [1] - The company posted revenues of $1.06 billion for the quarter, missing the Zacks Consensus Estimate by 2.63%, and a slight decrease from $1.07 billion year-over-year [2] Financial Performance - Over the last four quarters, Perrigo has surpassed consensus EPS estimates two times [2] - The company has not been able to beat consensus revenue estimates over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $1.12 billion, and for the current fiscal year, it is $3.04 on revenues of $4.44 billion [7] Stock Performance and Outlook - Perrigo shares have increased by approximately 3.5% since the beginning of the year, compared to the S&P 500's gain of 7.1% [3] - The company's earnings outlook and management's commentary on the earnings call will be crucial for future stock price movements [3][4] - The estimate revisions trend for Perrigo was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Perrigo belongs, is currently in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, Cresco Labs Inc., is expected to report a quarterly loss of $0.04 per share, with revenues projected to decline by 11.1% year-over-year [9]

Financial Performance - Net sales reached $1056 million, a decrease of 0.9% year-over-year[16] - Organic net sales experienced a slight decrease of 0.1% year-over-year[16] - Adjusted gross profit was $403 million, down 6.9% year-over-year[16] - Adjusted gross margin was 38.1%, a decrease of 250 basis points[16] - Adjusted operating income was $1352 million, down 2.9% year-over-year[16] - Adjusted EPS increased by 7.5% to $057[16] Segment Performance - Consumer Self-Care Americas (CSCA) net sales decreased by 1.9% year-over-year to $622 million[43] - Consumer Self-Care International (CSCI) net sales increased by 0.7% year-over-year to $4343 million[43] - Perrigo OTC brands grew by 3.6%, while Perrigo OTC store brands decreased by 3.2%[19] Strategic Initiatives - Infant formula net sales increased by 9% year-over-year[14] - Store brand and contract infant formula net sales increased by 32% year-over-year[26] - Project Energize is expected to deliver $159 million in annual run rate gross savings[30] - Supply Chain Reinvention is expected to generate total benefits between $150-$200 million by the end of 2025[30] - The sale of the Dermacosmetics business is expected to close in Q1 2026, with proceeds prioritized for accelerating net leverage goals[30, 52]

Financial Performance - Net sales for Q2 2025 were $1.06 billion, down 0.9% year-over-year, impacted by divestitures and exited products (-2.5%) and a slight decline in organic net sales (-0.1%) [3] - Adjusted EPS for Q2 2025 was $0.57, up 7.5% year-over-year, driven by lower interest expense from reduced debt, despite a $0.05 headwind from divestitures [25] - Reported operating income improved to $45 million from a loss of $27 million in the prior year, with an operating margin of 4.3%, an increase of 680 basis points year-over-year [23] - The company experienced a net loss of $1 million in Q2 2025, an improvement from a net loss of $106 million in the prior year [25] - Reported gross profit decreased by 8.1% to $363 million, with an adjusted gross margin of 38.1%, down 250 basis points year-over-year [21] - Reported operating income fell to $45 million, a decrease of $24 million or 34.9%, while adjusted operating income was $71 million, down 22.2% [30] - The company reported a net loss of $8.4 million for the three months ended June 28, 2025, compared to a net loss of $108.4 million for the same period in 2024 [65] - For the six months ended June 28, 2025, the net income was a loss of $14.8 million, compared to a loss of $106.4 million for the same period in 2024 [70] - Adjusted diluted earnings per share for the three months ended June 28, 2025, were $(0.06), improving from $(0.79) in the prior year [65] - Reported diluted loss per share for the six months ended June 28, 2025, was $(0.4), while adjusted diluted earnings per share were $1.17 [78] Sales and Revenue - Consumer Self-Care Americas segment reported net sales of $1.06 billion, down 1.9% year-over-year, with organic net sales also declining by 1.9% [26] - CSCA net sales for Q2 2025 were $622 million, a decline of $12 million or 1.9% year-over-year [29] - CSCI net sales increased by 0.7% to $434 million, driven by organic growth of 2.7% and favorable currency translation of 4.2% [36] - Reported net sales for the three months ended June 28, 2025, were $1,056.3 million, a slight decrease from $1,065.5 million for the same period in 2024 [72] - Reported net sales for the six months ended June 28, 2025, were $2,100.2 million, a decrease of 2.2% compared to $2,147.5 million for the same period in 2024 [78] - The net sales for Consumer Self-Care International were $857.4 million for the six months ended June 28, 2025, down 1.4% from $869.3 million in the prior year [100] - Organic net sales for the consolidated operations were $2,094.7 million for the six months ended June 28, 2025, reflecting a decrease of 0.3% compared to $2,100.1 million in the prior year [102] Cost and Expenses - The company estimates a gross increase to global cost of goods sold in 2025 of approximately $10 million to $20 million starting in Q4 [46] - The company incurred restructuring charges of $35.0 million for the six months ended June 28, 2025, slightly down from $38.3 million in the same period of 2024 [70] - The company incurred $70.0 million in amortization expenses related to acquired intangible assets during the six months ended June 28, 2025 [78] - The company recorded a total impairment charge of $3.1 million during the six months ended June 28, 2025, including a goodwill impairment charge of $1.2 million [79] - The total impairment charge for the three months ended June 28, 2025, was $1.5 million, compared to $34.1 million in the same quarter of 2024 [73] Strategic Initiatives - Project Energize is expected to deliver annualized pre-tax savings of $140 million to $170 million by the end of 2026, with gross annual savings of approximately $159 million achieved since its launch [13] - The sale of the Dermacosmetics business is expected to close in Q1 2026, with net proceeds aimed at strengthening the balance sheet and accelerating net leverage goals [11] - The company expects to continue experiencing restructuring-related charges as part of its strategic initiatives, impacting future financial performance [58] Cash Flow and Balance Sheet - Year-to-date operating cash flow was $11 million, with a cash inflow of $76 million in Q2 2025 [42] - Total debt on the balance sheet as of June 28, 2025, was $3.65 billion, with cash and cash equivalents at $454 million [44] - Cash and cash equivalents decreased to $454.2 million from $558.8 million at the end of 2024, reflecting a tighter liquidity position [68] - The company experienced a net decrease in cash and cash equivalents of $104.6 million, compared to a decrease of $208.5 million in the prior year [70] Tax and Non-GAAP Measures - Non-GAAP tax adjustments for the three months ended June 28, 2025, included $13.9 million of tax expense on pre-tax non-GAAP adjustments [92] - The effective tax rate for the six months ended June 28, 2025, was 103.6%, compared to 41.1% for the same period in 2024 [93] - The adjusted effective tax rate for the six months ended June 28, 2025, was 20.4%, compared to 20.2% for the same period in 2024 [93] - Management emphasizes the importance of non-GAAP measures to provide transparency and assess ongoing operational trends, which may assist investors in evaluating the company's performance [59]